s6y

Seres Therapeutics, Inc.

Ticker
MCRB
CIK
1609809
Industry
Pharmaceutical Preparations
Formerly
Seres Therapeutics, Inc., Seres Health, Inc.

Financials 46

  1. 10-Q Quarterly Report for period ending Sep 30, 2026
  2. 10-Q Quarterly Report for period ending Jun 30, 2026
  3. 10-Q Quarterly Report for period ending Mar 31, 2026
  4. 10-K Annual Report for period ending Dec 31, 2025
  5. 10-Q Quarterly Report for period ending Sep 30, 2025
  6. 10-Q Quarterly Report for period ending Jun 30, 2025
  7. 10-Q Quarterly Report for period ending Mar 31, 2025
  8. 10-K Annual Report for period ending Dec 31, 2024
  9. 10-Q Quarterly Report for period ending Sep 30, 2024
  10. 10-Q Quarterly Report for period ending Jun 30, 2024

All 46 financials filings

News 122

  1. 8-K Current report filing
  2. 8-K Current report filing
  3. 8-K Current report filing
  4. 8-K Current report filing
  5. 8-K Current report filing
  6. 8-K Current report filing
  7. 8-K Current report filing
  8. 8-K Current report filing
  9. 8-K Current report filing
  10. 8-K Current report filing

All 122 news filings

Ownership 441

  1. 4 Statement of changes in beneficial ownership of securities
  2. 4 Statement of changes in beneficial ownership of securities
  3. 4 Statement of changes in beneficial ownership of securities
  4. 4 Statement of changes in beneficial ownership of securities
  5. 4 Statement of changes in beneficial ownership of securities
  6. 4 Statement of changes in beneficial ownership of securities
  7. 4 Statement of changes in beneficial ownership of securities
  8. 4 Statement of changes in beneficial ownership of securities
  9. 4 Statement of changes in beneficial ownership of securities
  10. 4 Statement of changes in beneficial ownership of securities

All 441 ownership filings

Prospectus 43

  1. S-3 Registration statement for specified transactions by certain issuers
  2. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  3. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
  4. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
  5. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
  6. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  7. S-3 Registration statement for specified transactions by certain issuers
  8. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
  9. S-3 Registration statement for specified transactions by certain issuers
  10. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

All 43 prospectus filings

Proxies 35

  1. DEF 14A Definitive proxy statements
  2. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  3. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  4. DEF 14A Definitive proxy statements
  5. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition
  6. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  7. DEFM14A Definitive proxy statement relating to a merger, acquisition, or disposition
  8. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  9. PREM14A Preliminary proxy statement relating to a merger, acquisition, or disposition
  10. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.

All 35 proxies filings

Other 41

  1. EFFECT Notice of Effectiveness
  2. 144 Filing for proposed sale of securities under Rule 144
  3. 144 Filing for proposed sale of securities under Rule 144
  4. SCHEDULE 13G/A
  5. SCHEDULE 13G/A
  6. SCHEDULE 13G/A
  7. EFFECT Notice of Effectiveness
  8. CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
  9. UPLOAD Letter (PDF)
  10. EFFECT Notice of Effectiveness

All 41 other filings